Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 86% Improvement Relative Risk Hospitalization 93% primary Hazan et al. NCT04949230 Ivermectin LATE TREATMENT Is late treatment with ivermectin+combined treatments beneficial for COVID-19? Retrospective study in the USA Synthetic control arm Hazan et al., Future Microbiology, doi:10.2217/fmb-2022-0014 Favors ivermectin Favors control
Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients
Hazan et al., Future Microbiology, doi:10.2217/fmb-2022-0014 (date from earlier preprint), NCT04949230 (history)
Hazan et al., Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients, Future Microbiology, doi:10.2217/fmb-2022-0014 (date from earlier preprint), NCT04949230
Jul 2021   Source   PDF  
  All Studies   Meta
Small study of 24 consecutive patients in serious condition (9 days post symptoms, mean SpO2 87.4) using combined treatment with ivermectin, doxycycline, zinc, vitamin D, and vitamin C, showing no mortality or hospitalization with treatment. Two patients declined treatment and both died. This study uses a synthetic control arm. This study is excluded in the after exclusion results of meta analysis: study uses a synthetic control arm.
risk of death, 86.2% lower, RR 0.14, p = 0.04, NNT 6.9, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 93.5% lower, RR 0.07, p = 0.001, NNT 3.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hazan et al., 7 Jul 2021, retrospective, USA, peer-reviewed, 7 authors, average treatment delay 9.2 days, dosage 12mg days 1, 4, 8, this trial uses multiple treatments in the treatment arm (combined with doxycycline, zinc, vitamin D, vitamin C) - results of individual treatments may vary, trial NCT04949230 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Short Communication For reprint orders, please contact: Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients Sabine Hazan*,1 , Sonya Dave2 4 Peter A McCullough , Anoja W Gunaratne3 , Sibasish Dolai3 , Robert L Clancy3 , 3 & Thomas J Borody 1 ProgenaBiome, LLC, 1845 Knoll Dr., Ventura, CA 93003, USA 2 North End Advisory, 2451 Cumberland Pkwy SE Ste. 3152, Atlanta, GA 30339, USA 3 Centre for Digestive Diseases, 229 Great North Road, Five Dock, NSW, 2046, Australia 4 Truth for Health Foundation, Tucson, AZ 85728, USA *Author for correspondence: Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration: NCT04949230 ( First draft submitted: 15 January 2022; Accepted for publication: 25 January 2022; Published online: 9 February 2022 Keywords: coronavirus • COVID • doxycycline • ivermectin • SARS-CoV-2 • zinc There is currently a lack of effective treatments for early or ambulatory patients with COVID-19. Patients testing positive are sent home to isolate without specific treatment prescribed. However, there is growing evidence that certain repurposed drugs with good safety profiles, taken early, can significantly improve outcomes and even avoid or delay the need for immune-modulators, antiplatelet/antithrombotic therapy and the administration of oxygen [1]. Among the most extensively studied of such COVID-19 therapeutics is ivermectin (IVM), a drug that has been used safely in 3.7 billion doses worldwide since 1987 [2–4]. Recently, Dr Satoshi Omura, the 2015 Nobel Prize co-laureate for the discovery of IVM, and colleagues comprehensively reviewed studies to date on IVM activity against COVID-19, concluding that the evidence demonstrated such efficacy [4]. IVM used alone has been tested in more than 20 randomized, controlled trials (RCTs) for COVID-19 treatment, with statistically highly significant clinical benefits in almost all of these and an average of 62% reduction in risk of death [5]. Five such studies for IVM treatment of COVID-19 recently published in top-tier medical journals have all shown multiple clinical benefits for IVM versus controls, most of these with high statistical significance on the order of p < 0.002 [6–10]. At much greater than the standard single antiparasite dose of 200 μg/kg, IVM is well tolerated [11,12] and has been used in RCTs for COVID-19 treatment at cumulative doses of 1500 μg/kg [13] and 3000 μg/kg [14,15] over 4 or 5 days either without or with mild and transient adverse..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop